Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adsorption treatment in hyperlipidemia.

T Bosch1

  • 1Nephrological Department, University of Munich, Germany.

Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative genomics of ESBL-producing Escherichia coli (ESBL-Ec) reveals a similar distribution of the 10 most prevalent ESBL-Ec clones and ESBL genes among human community faecal and extra-intestinal infection isolates in the Netherlands (2014-17).

The Journal of antimicrobial chemotherapy·2021
Same author

Molecular characteristics of carbapenemase-producing Enterobacterales in the Netherlands; results of the 2014-2018 national laboratory surveillance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

[Carbapenemase producing Enterobacteriaceae in the Netherlands: unnoticed spread to several regions].

Nederlands tijdschrift voor geneeskunde·2017
Same author

Emergence of carbapenemase-producing Acinetobacter ursingii in The Netherlands.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

rRNA Operon Copy Number Can Explain the Distinct Epidemiology of Hospital-Associated Methicillin-Resistant Staphylococcus aureus.

Antimicrobial agents and chemotherapy·2016
Same author

Monitoring the spread of meticillin-resistant Staphylococcus aureus in The Netherlands from a reference laboratory perspective.

The Journal of hospital infection·2016

Selective LDL-adsorption therapies, including immunoadsorption and chemoadsorption, show significant progress for treating hypercholesterolemia and coronary artery disease. Newer whole-blood systems offer promising advancements for clinical plasma treatment.

Area of Science:

  • Cardiovascular Medicine
  • Biomedical Engineering
  • Nephrology

Background:

  • Hypercholesterolemia, particularly elevated low-density lipoprotein (LDL) levels, is a major risk factor for coronary artery disease (CAD).
  • Current treatments for severe hypercholesterolemia often involve lifestyle changes and pharmacotherapy, but some patients require more intensive interventions.
  • LDL apheresis, a method for selectively removing LDL cholesterol from the blood, has emerged as a valuable therapeutic option for specific patient groups.

Purpose of the Study:

  • To review the recent advancements in clinical LDL-adsorption technologies.
  • To highlight the efficacy and potential of various LDL-removal systems in managing hypercholesterolemia and CAD.
  • To discuss the future prospects of integrated and whole-blood LDL-adsorption devices.

Related Experiment Videos

Main Methods:

  • Review of clinical studies and laboratory research on LDL-adsorption techniques.
  • Description of immunoadsorption using polyclonal and monoclonal anti-LDL antibodies.
  • Explanation of chemoadsorption using the dextran sulfate system.
  • Discussion of integrated plasma separation/adsorption devices and LDL-hemoperfusion modules.

Main Results:

  • Successful clinical application of immunoadsorption (polyclonal anti-LDL antibodies) and chemoadsorption (dextran sulfate) for selective LDL removal in hypercholesterolemic CAD patients.
  • Positive results from clinical pilot studies using immunoadsorption with anti-LDL-F(ab)-columns.
  • Promising laboratory findings with immunoadsorption using monoclonal LDL antibodies, polyacrylate/fractogel, and macroporous cellulose.
  • Development of integrated devices and LDL-hemoperfusion modules capable of treating whole blood, bypassing the need for initial plasma separation.

Conclusions:

  • Clinical LDL-adsorption therapies have demonstrated significant progress and effectiveness.
  • Various immunoadsorption and chemoadsorption systems are successfully applied in routine clinical practice.
  • Emerging whole-blood LDL-adsorption technologies hold great promise for future therapeutic applications in managing hypercholesterolemia and CAD.